Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease

NCT02244541 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: ANAVEX2-73 Oral
DRUG: ANAVEX2-73 Intravenous
DRUG: ANAVEX2-73 Oral
DRUG: ANAVEX2-73 Oral

Sponsor

Anavex Life Sciences Corp.